3 results on '"Wedren, S."'
Search Results
2. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006
- Author
-
Holmqvist, ME, Wedren, S, Jacobsson, LTH, Klareskog, L, Nyberg, F, Rantapää-Dahlqvist, Solbritt, Alfredsson, L, Askling, J, Holmqvist, ME, Wedren, S, Jacobsson, LTH, Klareskog, L, Nyberg, F, Rantapää-Dahlqvist, Solbritt, Alfredsson, L, and Askling, J
- Abstract
Holmqvist ME, Wedren S, Jacobsson LTH, Klareskog L, Nyberg F, Rantapaa-Dahlqvist S, Alfredsson L, Askling J (Institute of Environmental Medicine, Karolinska Institutet, Stockholm; Karolinska Institutet/Karolinska Hospital, Stockholm; Malmo University Hospital, Malmo; AstraZeneca R&D, Molndal; and Umea University Hospital, Umea, Sweden) Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 2010; 268: 578-585. The risk of ischaemic heart disease (IHD), and in particular myocardial infarction (MI), is increased amongst patients with established rheumatoid arthritis (RA). Few studies have included contemporary patients with RA. We recently reported that the risk of IHD is not elevated before the onset of RA symptoms. However, when, in relation to RA diagnosis, the risk is increased is unknown. Objective. To assess the risk of MI and other IHD events amongst patients diagnosed with RA during the last decade and within 18 months following RA symptom onset, compared to the general population, by time since RA diagnosis, year of RA diagnosis and by rheumatoid factor (RF) status. Methods and patients. A Swedish inception cohort of RA (n = 7469) diagnosed between 1995 and 2006 and a matched general population comparator cohort (n = 37 024), was identified and linked to national registers of morbidity and mortality from IHD. Relative risks (RRs) of MI and other IHD events were estimated using Cox regression. Results. During follow-up, 233 patients with RA and 701 controls developed a first MI, corresponding to an overall RR of MI of 1.6 (95% confidence interval 1.4, 1.9). Increased risks of MI were already detected within 1-4 years following RA diagnosis, as well as in patients diagnosed with RA during the last 5 years, in RF-negative patients and for transmural as well as nontransmural MIs. Conclusions. MI risk increases rapidly following RA diagnosis, suggesting the importan
- Published
- 2010
- Full Text
- View/download PDF
3. Genome-wide association study identifies novel breast cancer susceptibility loci.
- Author
-
Cox A., Farshid G., Fawcett S., Field M., Firgaira F., Fleming J., Forbes J., Friedlander M., Gaff C., Gardner M., Gattas M., George P., Gill G., Goldblatt J., Greening S., Haan E., Hart S., Humphrey E., Jenkins M., Kefford R., Kirk J., Kollias J., Kovalenko S., Lakhani S., Leary J., Lim J., Lindeman G., Lipton L., Lobb L., Maclurcan M., Marsh D., McKay M., Anne McLachlan S., Mitchell G., Newman B., O'Loughlin I., Osborne R., Peters L., Price M., Reeve J., Reeve T., Richards R., Rinehart G., Robinson B., Rudzki B., Salisbury E., Saunders C., Scott E., Seshadri R., Shelling A., Suthers G., Taylor D., Tennant C., Townshend S., Tyler J., Venter D., Visvader J., Walpole I., Ward R., Warner B., Warren G., Watson E., Williams R., Winship I., Bowtell D., Green A., DeFazio A., Gertig D., Webb P., Milne R., Young M.A., Harris M., Wilson J., Easton D.F., Pooley K.A., Dunning A.M., Pharoah P.D.P., Thompson D., Ballinger D.G., Struewing J.P., Morrison J., Field H., Luben R., Wareham N., Ahmed S., Healey C.S., Bowman R., Meyer K.B., Haiman C.A., Kolonel L.K., Henderson B.E., Le Marchand L., Brennan P., Sangrajrang S., Gaborieau V., Odefrey F., Shen C.-Y., Wu P.-E., Wang H.-C., Eccles D., Evans D.G., Peto J., Fletcher O., Johnson N., Seal S., Stratton M.R., Rahman N., Chenevix-Trench G., Bojesen S.E., Nordestgaard B.G., Axelsson C.K., Garcia-Closas M., Brinton L., Chanock S., Lissowska J., Peplonska B., Nevanlinna H., Fagerholm R., Eerola H., Kang D., Yoo K.-Y., Noh D.-Y., Ahn S.-H., Hunter D.J., Hankinson S.E., Cox D.G., Hall P., Wedren S., Liu J., Low Y.-L., Bogdanova N., Schurmann P., Dork T., Tollenaar R.A.E.M., Jacobi C.E., Devilee P., Klijn J.G.M., Sigurdson A.J., Doody M.M., Alexander B.H., Zhang J., Brock I.W., MacPherson G., Reed M.W.R., Couch F.J., Goode E.L., Olson J.E., Meijers-Heijboer H., Van Den Ouweland A., Uitterlinden A., Rivadeneira F., Milne R.L., Ribas G., Gonzalez-Neira A., Benitez J., Hopper J., McCredie M., Southey M., Giles G., Schroen C., Justenhoven C., Brauch H., Hamann U., Ko Y.-D., Spurdle A.B., Beesley J., Chen X., Mannermaa A., Kosma V.-M., Kataja V., Hartikainen J., Day N.E., Cox D.R., Ponder B.A.J., Luccarini C., Conroy D., Shah M., Munday H., Jordan C., Perkins B., West J., Redman K., Driver K., Aghmesheh M., Amor D., Andrews L., Antill Y., Armes J., Armitage S., Arnold L., Balleine R., Begley G., Beilby J., Bennett I., Bennett B., Berry G., Blackburn A., Brennan M., Brown M., Buckley M., Burke J., Butow P., Byron K., Callen D., Campbell I., Clarke C., Colley A., Cotton D., Cui J., Culling B., Cummings M., Dawson S.-J., Dixon J., Dobrovic A., Dudding T., Edkins T., Eisenbruch M., Cox A., Farshid G., Fawcett S., Field M., Firgaira F., Fleming J., Forbes J., Friedlander M., Gaff C., Gardner M., Gattas M., George P., Gill G., Goldblatt J., Greening S., Haan E., Hart S., Humphrey E., Jenkins M., Kefford R., Kirk J., Kollias J., Kovalenko S., Lakhani S., Leary J., Lim J., Lindeman G., Lipton L., Lobb L., Maclurcan M., Marsh D., McKay M., Anne McLachlan S., Mitchell G., Newman B., O'Loughlin I., Osborne R., Peters L., Price M., Reeve J., Reeve T., Richards R., Rinehart G., Robinson B., Rudzki B., Salisbury E., Saunders C., Scott E., Seshadri R., Shelling A., Suthers G., Taylor D., Tennant C., Townshend S., Tyler J., Venter D., Visvader J., Walpole I., Ward R., Warner B., Warren G., Watson E., Williams R., Winship I., Bowtell D., Green A., DeFazio A., Gertig D., Webb P., Milne R., Young M.A., Harris M., Wilson J., Easton D.F., Pooley K.A., Dunning A.M., Pharoah P.D.P., Thompson D., Ballinger D.G., Struewing J.P., Morrison J., Field H., Luben R., Wareham N., Ahmed S., Healey C.S., Bowman R., Meyer K.B., Haiman C.A., Kolonel L.K., Henderson B.E., Le Marchand L., Brennan P., Sangrajrang S., Gaborieau V., Odefrey F., Shen C.-Y., Wu P.-E., Wang H.-C., Eccles D., Evans D.G., Peto J., Fletcher O., Johnson N., Seal S., Stratton M.R., Rahman N., Chenevix-Trench G., Bojesen S.E., Nordestgaard B.G., Axelsson C.K., Garcia-Closas M., Brinton L., Chanock S., Lissowska J., Peplonska B., Nevanlinna H., Fagerholm R., Eerola H., Kang D., Yoo K.-Y., Noh D.-Y., Ahn S.-H., Hunter D.J., Hankinson S.E., Cox D.G., Hall P., Wedren S., Liu J., Low Y.-L., Bogdanova N., Schurmann P., Dork T., Tollenaar R.A.E.M., Jacobi C.E., Devilee P., Klijn J.G.M., Sigurdson A.J., Doody M.M., Alexander B.H., Zhang J., Brock I.W., MacPherson G., Reed M.W.R., Couch F.J., Goode E.L., Olson J.E., Meijers-Heijboer H., Van Den Ouweland A., Uitterlinden A., Rivadeneira F., Milne R.L., Ribas G., Gonzalez-Neira A., Benitez J., Hopper J., McCredie M., Southey M., Giles G., Schroen C., Justenhoven C., Brauch H., Hamann U., Ko Y.-D., Spurdle A.B., Beesley J., Chen X., Mannermaa A., Kosma V.-M., Kataja V., Hartikainen J., Day N.E., Cox D.R., Ponder B.A.J., Luccarini C., Conroy D., Shah M., Munday H., Jordan C., Perkins B., West J., Redman K., Driver K., Aghmesheh M., Amor D., Andrews L., Antill Y., Armes J., Armitage S., Arnold L., Balleine R., Begley G., Beilby J., Bennett I., Bennett B., Berry G., Blackburn A., Brennan M., Brown M., Buckley M., Burke J., Butow P., Byron K., Callen D., Campbell I., Clarke C., Colley A., Cotton D., Cui J., Culling B., Cummings M., Dawson S.-J., Dixon J., Dobrovic A., Dudding T., Edkins T., and Eisenbruch M.
- Abstract
Breast cancer exhibits familial aggregation, consistent with variation in genetic susceptibility to the disease. Known susceptibility genes account for less than 25% of the familial risk of breast cancer, and the residual genetic variance is likely to be due to variants conferring more moderate risks. To identify further susceptibility alleles, we conducted a two-stage genome-wide association study in 4,398 breast cancer cases and 4,316 controls, followed by a third stage in which 30 single nucleotide polymorphisms (SNPs) were tested for confirmation in 21,860 cases and 22,578 controls from 22 studies. We used 227,876 SNPs that were estimated to correlate with 77% of known common SNPs in Europeans at r2> 0.5. SNPs in five novel independent loci exhibited strong and consistent evidence of association with breast cancer (P < 10-7). Four of these contain plausible causative genes (FGFR2, TNRC9, MAP3K1 and LSP1). At the second stage, 1,792 SNPs were significant at the P < 0.05 level compared with an estimated 1,343 that would be expected by chance, indicating that many additional common susceptibility alleles may be identifiable by this approach. ©2007 Nature Publishing Group.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.